文献速递肿瘤 PET/CT

68Ga-PSMA-11 PET在生化复发前列腺癌中的综合评估:2005例前瞻性多中心研究

A Comprehensive Assessment of 68Ga-PSMA-11 PET in Biochemically Recurrent Prostate Cancer: Results from a Prospective Multicenter Study on 2,005 Patients.
PubMed 文献 · J Nucl Med · 2021-07-29

该前瞻性多中心研究纳入2005例根治性前列腺切除或放疗后生化复发的前列腺癌患者,评估68Ga-PSMA-11 PET的检出率与阳性预测值。结果显示检出率随PSA水平升高而显著增加,患者水平PPV为0.82,证实PSA是扫描阳性的主要预测因素。

要点

  • 根治性切除后检出率从PSA<0.25 ng/mL的44.8%升至>10 ng/mL的96.2%。
  • 组织病理验证的患者水平PPV为0.82(146/179)。
  • 真阳性病灶SUVmax中位11.0显著高于假阳性5.1。

核心结论

  • 68Ga-PSMA-11 PET在生化复发前列腺癌中具有高阳性预测值,PSA水平是扫描阳性的主要预测因素。

研究设计与样本

  • 前瞻性多中心研究,纳入2005例生化复发前列腺癌患者,均行68Ga-PSMA-11混合PET。
  • 患者既往治疗包括根治性前列腺切除(50.8%)、根治性放疗(19.7%)及切除联合术后放疗(29.6%)。
  • 主要研究终点为经组织病理学证实的68Ga-PSMA-11 PET/CT阳性预测值。

主要发现

  • 根治性切除后,扫描检出率随PSA水平升高而显著增加,从PSA<0.25 ng/mL的44.8%至PSA>10 ng/mL的96.2%(P<0.001)。
  • 检出率在各单独区域、总体疾病负荷、既往雄激素剥夺、临床T分期及根治标本Gleason分级中均随PSA升高而显著增加(P<0.001)。
  • 放疗后腺内前列腺复发检出率为64.0%,根治性切除后前列腺床复发为20.6%,术后放疗后为13.3%。
  • PSMA阳性盆腔淋巴结病变检出率在根治性切除后为42.7%,术后放疗后为40.8%,放疗后为38.8%。
  • 组织病理验证的患者水平PPV为0.82(146/179);组织学证实真阳性病灶SUVmax中位11.0(IQR 6.3-22.2)显著高于假阳性5.1(IQR 2.2-7.4)(P<0.001)。

临床怎么用

  • 对于生化复发前列腺癌患者,68Ga-PSMA-11 PET可用于定位复发灶,PSA水平有助于预判扫描阳性概率。
  • 真阳性病灶SUVmax中位11.0高于假阳性5.1,可辅助鉴别。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We prospectively investigated the performance of the prostate-specific membrane antigen (PSMA) ligand 68Ga-PSMA-11 for detecting prostate adenocarcinoma in patients with elevated levels of prostate-specific antigen (PSA) after initial therapy. Methods:68Ga-PSMA-11 hybrid PET was performed on 2,005 patients at the time of biochemically recurrent prostate cancer after radical prostatectomy (RP) (50.8%), definitive radiation therapy (RT) (19.7%), or RP with postoperative RT (PORT) (29.6%). The presence of prostate cancer was assessed qualitatively (detection rate = positivity rate) and quantitatively on a per-patient and per-region basis, creating a disease burden estimate from the presence or absence of local (prostate/prostate bed), nodal (N1: pelvis), and distant metastatic (M1: distant soft tissue and bone) disease. The primary study endpoint was the positive predictive value (PPV) of 68Ga-PSMA-11 PET/CT confirmed by histopathology. Results: After RP, the scan detection rate increased significantly with rising PSA level (44.8% at PSA < 0.25%-96.2% at PSA > 10 ng/mL; P < 0.001). The detection rate significantly increased with rising PSA level in each individual region, overall disease burden, prior androgen deprivation, clinical T-stage, and Gleason grading from the RP specimen (P < 0.001). After RT, the detection rate for in-gland prostate recurrence was 64.0%, compared with 20.6% prostate bed recurrence after RP and 13.3% after PORT. PSMA-positive pelvic nodal disease was detected in 42.7% after RP, 40.8% after PORT, and 38.8% after RT. In patients with histopathologic validation, the PPV per patient was 0.82 (146/179). The SUVmax of histologically proven true-positive lesions was significantly higher than that of false-positive lesions (median, 11.0 [interquartile range, 6.3-22.2] vs. 5.1 [interquartile range, 2.2-7.4]; P < 0.001). Conclusion: We confirmed a high PPV for 68Ga-PSMA-11 PET in biochemical recurrence and the PSA level as the main predictor of scan positivity.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Abghari-Gerst M, Armstrong WR, Nguyen K, et al. A Comprehensive Assessment of 68Ga-PSMA-11 PET in Biochemically Recurrent Prostate Cancer: Results from a Prospective Multicenter Study on 2,005 Patients. J Nucl Med. 2021. PMID: 34326126. doi:10.2967/jnumed.121.262412

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。